All patients | No radiographic progression | Radiographic progression | P valuea | |
---|---|---|---|---|
Number | 149 | 131 | 18 | |
Age, years, mean (SD) | 58.15 (12.58) | 57.60 (12.71) | 62.22 (11.01) | 0.11 |
Female, n (%) | 123 (82.6) | 108 (82.4) | 15 (83.3) | 0.61 |
Disease duration, years, median (IQR) | 13.00 (8.00; 21.00) | 13.00 (8.00; 20.50) | 13.50 (8.50; 30.75) | 0.41 |
Previous anti-TNFα failures, n (%) | 30 (20.1) | 26 (19.9) | 4 (22.2) | 0.51 |
Positive ACPA and/or RF, n (%) | 76 (51.0) | 65 (49.6) | 11 (61.1) | 0.36 |
Smokers or ex-smokers, n (%) | 39 (26.2) | 35 (26.7) | 4 (22.2) | 0.47 |
TSS progression per year before baseline, median (IQR) | 8.00 (5.00; 11.63) | 7.32 (5.00; 11.10) | 10.25 (7.38; 15.50) | 0.02 |
ADA treatments, n (%) | 56 (37.6) | 48 (36.6) | 8 (44.4) | 0.59 |
ETA treatments, n (%) | 93 (62.4) | 83 (63.4) | 10 (55.6) | 0.59 |
Low dose biologic, n (%) | 103 (69.1) | 89 (67.9) | 14 (77.8) | 0.40 |
Concurrent DMARD use, n (%) | 76 (51.0) | 66 (50.4) | 10 (55.6) | 0.68 |
PDN daily dose, mg, median (IQR) | 1.00 (0.74; 2.00) | 1.00 (0.60; 2.00) | 1.50 (0.75; 2.00) | 0.99 |
TSS progression at the 24-month follow up, median (IQR) | 0 (0) | 0 (0) | 2.00 (2.00; 14.00) | <0.01 |
Baseline | ||||
HAQ, mean (SD) | 0.74 (0.40) | 0.73 (0.41) | 0.87 (0.25) | 0.08 |
DAS28, median (IQR) | 2.21 (1.92; 2.38) | 2.24 (1.85; 2.38) | 2.05 (2.05; 2.38) | 0.53 |
CRP, mg/L, median (IQR) | 3.00 (1.00; 4.00) | 3.00 (1.00; 4.00) | 1.00 (1.00; 4.00) | 0.24 |
TJC, median (IQR) | 1 (0; 2) | 1 (0; 2) | 1 (1; 1) | 0.70 |
SJC, median (IQR) | 0 (0) | 0 (0) | 0 (0) | – |
Patient-VAS, mm, median (IQR) | 20 (15; 20) | 20 (10; 30) | 20 (0) | 0.23 |
Follow up, 24 months | ||||
HAQ, median (IQR) | 0.74 (0.39) | 0.73 (0.40) | 0.85 (0.23) | 0.18 |
DAS28, median (IQR) | 2.16 (1.80; 2.43) | 2.18 (1.80; 2.63) | 1.85 (1.82; 2.42) | 0.52 |
CRP, mg/L, median (IQR) | 2.00 (1.00; 3.00) | 2.00 (1.00; 3.00) | 2.00 (2.00; 3.00) | 0.29 |
TJC, median (IQR) | 1 (0; 2) | 1 (0; 2) | 0 (0; 1) | 0.24 |
SJC, median (IQR) | 0 (0) | 0 (0) | 0 (0) | – |
Patient-VAS, mm, median (IQR) | 20 (10; 30) | 20 (10; 30) | 33 (28; 35) | 0.01 |
Change between baseline and 24-month follow up | ||||
HAQ, median (IQR) | 0 (−0.10; 0.07) | 0 (−0.11; 0.07) | 0.01 (−0.05; 0.05) | 0.56 |
DAS28, mean (SD) | −0.13 (0.55) | 0 (0.58) | −0.02 (0.30) | 0.63 |
CRP, mg/L, median (IQR) | 0 (−2.00; −2.00) | 0 (−3.00; 2.00) | 1.00 (−1.00; 1.00) | 0.11 |
TJC, median (IQR) | 0 (−1; −1) | 0 (−1; −1) | −1 (−1; 0) | 0.28 |
SJC, median (IQR) | 0 (0) | 0 (0) | 0 (0) | – |
Patient-VAS, mm, median (IQR) | 5 (−5; 10) | 0 (−10; 10) | 13 (9; 15) | <0.01 |